Meet our Faculty Prof. Amos Toren

Prof. Amos Toren

Sheba Medical Center, Tel Hashomer, Israel
Amos Toren 130X130

Professor Amos Toren is the director of Pediatric Hemato-Oncology and BMT Department at the Sheba Medical Center since 2001. During this period the scope of activities of the Department enlarged substantially and it became the largest of its kind in Israel. In addition he implemented innovative therapeutic modalities in addition to conventional modern therapies in the fields of chemotherapy, immunotherapy and stem cell transplantation. The standard of therapy given in the department at present time is aligned to the therapy given in the most advanced centers in the western world.
Dr Toren is an Professor in the division of Hematology, Sackler School of Medicine Tel-Aviv University. He served as the Head of this division for 2 terms. Professor Toren is a specialist in Pediatrics, General Hematology and Pediatric Hemato-Oncology.
He also has a PhD degree in genetics and qualified as a Master of Health Administration (MHA) at the Recannati Business School, Tel-Aviv University. Professor Toren runs many clinical studies, investigator initiated, companies initiated, unicenter as well as multicenter.
Incorporation of new treatment modalities:
Blinatumomab(bi-specific antibody) and Eparatuzumab (anti-CD22 antibody) for the treatment of relapse/refractory lymphoblastic leukemia.
Anti-GD2 antibody for high-risk neuroblastoma.
Proteosome inhibitor (Carfilzumib) for relapse leukemia.
Dabafenib for patients with BRAF mutation.
Checkpoint inhibitors (Pembrolizumab) for patients who express PDL1.
Recently he became the principal investigator in the study of T- CARs for patients with relapse/refractory ALL in collaboration with Ella institute and the NIH. This innovate treatment is being used only in few centers in the US.
Prof. Toren made a lot of efforts to the establishment of Genetic counseling clinic which is an integral part of the department and is based on the analysis of cancer predisposing genes in genetic panels and whole exome sequencing (WES). The analysis is performed in the institute of cancer research in Sheba.
Professor Toren he published 107 original articles, many case reports, chapters in books, participated and lectured in many meetings all over the world. Professor Toren devotes a lot of his time to students education whether at bedside, University (he now runs the Pediatric Hemato-Oncology course which is a part of the Pediatrics Continuation course).
He guided many research students )PhD, Master, MD, Basic Science in Pediatrics) He participates regularly in promotion committees of the members of the Tel-Aviv University staff, and is a reviewer of grant application. He is also a reviewer of many journals in the fields of Hematology, Pediatric Hemato-Oncology and BMT. He recently was granted by 3 prestigious funds: The Boaz Dotan grants this year and the previous one and the Gestner grant this year.
Professor Toren is the head of a busy research lab. He now has 4 PhD students and 2 Master students under his responsibility. Professor Toren’s research lab focuses on:
1. Pediatric brain tumors- pathogenesis, innovative therapies, discovery of new molecular aberrations, new biomarkers, new therapeutic targets the effect of new drugs on cell lines, primary cells and xenografts, studying the influence of changes in the levels of non-coding RNA’s (mirs and link-RNA) on the tumor .
2. The usage of different Cannabinoids in pediatric tumors cell lines, primary cells and xenografts. He also runs clinical studies incorporating cannabinoids in the management of nausea, vomiting, improval of appetite and mucositis.
3. Hematopoietic stem cell as well as tumor initiating cells in pediatric tumors. He recently developed in cooperation with the Dekel group a platform to identify, isolate and targeted therapy by late passages of patient derived xenografts.
4. Immunotherapy-The recent focus of this topics is the improvement of the activity of cytokine induced killer cells (CIKS) aiming to improve their ability to combat pediatric tumors. This is done by priming of the CIKS by irradiated tumor cells.
5. Studying the molecular mechanisms that modulate the response of pediatric GBM to anti- neoplastic treatments. Two hypotheses will be studied:
1. A sustained increase in eIF2α phosphorylation in pediatric HGG (high grade glioma) expressing H3.3G34R/V is detrimental to their survival and increases their sensitivity to anti-neoplastic treatments.
2. Expression of H3.3G34R/V which diminishes tri-methylation of H3K36 on the tail of the mutated protein compromises MMR in the cells leading to increased microsatellite instability (MSI).